Screening for ALK rearrangements has become a very important process in treatment decision making for advanced NSCLC [28] and mutation tests of these genes, including their rearrangements, are part of cancer gene therapy strategies for NSCLC patients [29]. This evidence concerns the gene ALK and non-small cell lung carcinoma.